Kimberly J. Van Zee, MS, MD, FACS, discusses tough decisions women with a Ductal carcinoma in situ (DCIS) diagnosis face. While DCIS is considered to be a better diagnosis than invasive breast cancer, it also can be a confusing one, and patients facing DCIS often find it very difficult to choose among different treatment options. 

Videos

Kimberly J. Van Zee, MS, MD, FACS, discusses difficult decisions women with a Ductal carcinoma in situ (DCIS) diagnosis face.

Kimberly J. Van Zee on Difficult Decisions Decisions With a DCIS Diagnosis

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ductal carcinoma in situ (DCIS).

DCIS, often considered stage 0 breast cancer, is one step before invasive breast cancer and can be treated by radiation, drugs or mastectomy to minimize chance of recurrence. However, Van Zee emphasizes that not many women want to undergo these treatments at such an early stage. 

The nomogram is a tool that patients and their health care providers can use to estimate risk of recurrence, so that appropriate treatment decisions can be made. 

Kimberly J. Van Zee, MS, MD, FACS

Articles

Kimberly J. Van Zee on Difficult Decisions Decisions With a DCIS Diagnosis

Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making